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Purpose: To detect and quantify the immunoreactivity of TCF4 protein in colorectal carci-
noma, colorectal adenoma and non-neoplasic colorectal epithelium. 
Methods: We studied 129 individuals: 40 with colorectal cancer, 52 with colorectal ad-
enoma and 37 with non-neoplastic colorectal epithelium. The colorectal adenoma and 
carcinoma samples were obtained from patients who underwent surgical procedures, 
and colonoscopies and samples of non-neoplastic colorectal epithelium were taken from 
patients who died from cardiovascular diseases, without diseases of the large intestine. 
Samples of different tissues were included in paraffi n blocks, and the immunohistochem-
ical expression of protein TCF4 was analyzed using the technique of tissue microarray 
(TMA) with polyclonal antibody TCF4. The immunoreactivity was analyzed and classifi ed 
as positive and negative. 
Results: The immunohistochemical expression of TCF4 protein was signifi cantly higher 
(p < 0.01) in colorectal carcinoma than in the non-neoplastic colorectal epithelium and 
adenoma. There was no difference (p = 0.76) between TCF4 protein immunohistochemical 
expression in colorectal adenoma and non-neoplastic colorectal tissue. 
Conclusions: TCF4 protein showed a more intense expression in colorectal carcinoma than 
in non-neoplastic colorectal epithelium and adenoma, indicating that this protein is in-
volved in colorectal carcinogenesis.
© 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. 
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r e s u m o
Expressão imuno-histoquímica da proteína TCF4 no carcinoma,  
no adenoma e na mucosa não neoplásica colorretal 
Objetivos: Detectar e quantificar a imunoexpressão da proteína TCF4 no carcinoma e no 
adenoma colorretal e no epitélio colorretal não neoplásico. 
Método: Foram estudados 129 indivíduos: 40 com carcinoma colorretal, 52 com adenoma 
colorretal e 37 com epitélio colorretal não neoplásico. Os tecidos de adenoma e carcinoma 
colorretais foram representados por amostras da lesão retirada de doentes submetidos a 
procedimentos cirúrgicos e colonoscópicos, e as amostras de epitélio colorretal não neo-
plásico foram retiradas de doentes falecidos por afecções cardiovasculares e sem compro-
metimento do intestino grosso. As amostras dos diferentes tecidos foram incluídas em blo-
cos de parafina e submetidas ao estudo da imunoexpressão da proteína TCF4 pela técnica 
do tissue microarray (TMA) com o anticorpo policlonal anti-TCF4. A imunorreatividade foi 
analisada e classificada como positiva e negativa. 
Resultados: A imunoexpressão da proteína TCF4 foi significantemente maior (p < 0,01) no 
carcinoma colorretal do que nos adenomas e no epitélio colorretal não doente. Não houve 
diferença significante (p = 0,76) entre a imunoexpressão da proteína TCF4 no adenoma co-
lorretal e no epitélio colorretal não doente. 
Conclusão: A maior expressão da proteína TCF4 no carcinoma colorretal em relação ao ade-
noma e ao epitélio não doente sugere que esta proteína possui participação na carcinogê-
nese colorretal.
© 2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda. 
Introduction
With the increase in the average age of the world popu-
lation in recent years, an increase of causes of death by 
neoplastic diseases was observed. Among these diseases, 
colorectal cancer (CRC) become prominent, especially in 
the western hemisphere population. About 50% of individ-
uals will develop colorectal adenoma until the age of 70, 
and one in ten adenomas will progress to carcinoma.1 In 
Brazil, 30,140 new cases of CRC will emerge, according to 
estimates: 14,180 in men and 15,960 in women, and half of 
these people will die from the disease.2
The sequence non-neoplastic colorectal tissue-ade-
noma-carcinoma was first described by Fearon and Vol-
geistein,3 in 1978, and prompted studies to determine the 
genetic and epigenetic alterations of this transformation. 
However, the molecular changes involved in this process 
are still not fully understood.
The Wnt signalling pathway plays an important role in 
the development of the human embryo, participating in 
the formation and homeostasis of organs and tissues. The 
improper functioning of this pathway participates in the 
carcinogenesis of human tissues, including colorectal tis-
sue.4 When the Wnt pathway is activated, in most cases by 
mutations of proteins members of the pathway itself, the 
usual result is an increase of the transcription of genes im-
portant for growth, proliferation, differentiation, apoptosis, 
genetic stability, migration and angiogenesis.5 About 200 
genes that are influenced by this pathway, including genes 
c-myc, cyclin D1,6 VEGF (vascular endothelial growth factor) 
and endothelin, were described.
The TCF/LEF family controls a great number of genes ac-
tivated by Wnt. In this family, TCF4 gene is the component 
most commonly expressed in human colorectal tissue and 
is responsible for the activation of several genes linked to 
colorectal carcinogenesis, acting either in the more early 
stages (transformation of normal colorectal tissue to ad-
enoma) as in later phases (distant metastases).7,8 Recently, 
studies consistently showed evidence of the influence of 
this gene in colorectal carcinogenesis. This gene exhibits a 
mutation 2.8 times more frequent in the CRC than in non-
neoplastic colorectal tissue.9 Another study showed that 
when overexpression of anti-TCF-4 occurred, colorectal 
tumours did not present a satisfactory response to neoad-
juvant therapy,10 and when TCF4 is inhibited using inter-
ference RNA, an increased sensitivity of CRC to treatment 
occurs.11
Because of this evidence, it becomes important to define 
patterns of expression of this protein in various types of 
colorectal tissue through a simpler, cheaper and more af-
fordable method. 
The aim of this study is the detection, by immunohis-
tochemical method, of TCF4 protein, a member of the Wnt 
signalling pathway in colorectal adenoma and carcinoma 
and in non-neoplastic colorectal epithelium.
Methods
All patients agreed to participate in the project by signing the 
Statement of Informed Consent. The study was approved by 
the Ethics Committee in Research of UNIFESP and HFSE-RJ, as 
protocol: CEP 000 450. 
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This is a retrospective study conducted at the Serviço de Co-
loproctologia, Hospital Federal dos Servidores do Estado do Rio 
de Janeiro (HFSE), in which 163 paraffi n blocks were analyzed 
in three groups: group 1 (carcinoma) with 46 blocks of patients 
with CRC operated, group 2 (adenoma) with 67 blocks of pa-
tients who underwent endoscopic or surgical polypectomy, and 
group 3 (control) with 50 blocks of patients who died from heart 
disease and without indicative picture of digestive disease, and 
necropsied at the Serviço de Verifi cação de Óbitos do Município 
de São Paulo (SVO - Universidade de São Paulo - USP).
For the formation of groups 1 and 2, patients treated in 
HFSE-RJ and who underwent colonoscopy or surgical proce-
dures and were in outpatient follow-up during the study period 
were included.
Subjects under 18 years of age, patients with infl ammatory 
bowel disease or with non-adenomatous polyps and those who 
refused to participate in the study were excluded; 13 of 50 sam-
ples from non-neoplastic colorectal tissue were excluded due 
to non-recognition of the colorectal mucosa or due to autolysis 
found in these samples; of 67 cases of colorectal adenomas, 15 
were excluded due to the observation of only hyperplasic epi-
thelium; and, fi nally, of 46 carcinoma blocks 6 were excluded, 
due to samples that, on analysis, did not include areas with car-
cinomatous transformation.
From the paraffi n blocks obtained by the procedures above, 
blocks of tissue micro array (TMA) were prepared. The prepara-
tion of TMA blocks followed the technique described by Pires 
et al.12 Three blocks were prepared : the fi rst with the cases of 
colorectal carcinoma, the second with colorectal adenomas 
and the third block with non-neoplastic colorectal tissue. 
For the immunohistochemistry method, histological sec-
tions of 3 mm thick were obtained; they were deposited on si-
lanized slides and subsequently treated by streptavidin-biotin 
method.
Incubation with primary antibody was performed in a moist 
chamber at 4°C for a minimum of 16-18 hours (overnight), at a 
1:10 dilution. The primary antibody used was polyclonal TCF-4 
(NBP1-88633) obtained from rabbit (Novus Biologicals, Littleton, 
CO, USA). 
The immunoreactivity of TCF4 protein was analyzed and 
classifi ed as positive or negative.
The following data were recorded: clinical features of sam-
ple (age and gender) for all groups of individuals. In the group 
of patients with colorectal adenoma, the morphological charac-
teristics of the lesion (location, size of the longer axis, histologi-
cal type, degree of cellular atypia) were recorded. In the group 
of patients with colorectal carcinoma, macroscopic lesion char-
acteristics (location, appearance, size of the longer axis), mi-
croscopic features (lymph node involvement, grade of cellular 
differentiation, lymphatic, venous and neural infi ltration), TNM 
classifi cation (UICC, 2010),13 presence of synchronous metasta-
ses and tissue immunoexpression of the antibodies used (nega-
tive or positive) were registered.
Statistical analysis of the quantitative results was reported 
as mean and standard deviation. The qualitative data were 
described as frequency. To analyze categorical variables, the 
Fisher exact test or the chi-square test was used; and for con-
tinuous variables, the Student's t test was used, after testing for 
its normality. 
The level of signifi cance was set at 5% (p < 0.05) in all tests.
Results
This is a retrospective study in which three groups of sub-
jects were studied, of which data of two groups were col-
lected at HFSE-RJ, and data of the third group at SVO-USP. In 
both institutions the data were collected sequentially, with 
no attempt to matching among the groups with disease and 
the control group. No signifi cant differences between groups 
in relation to clinical characteristics were found (Fig. 1).
Fifty-two subjects with colorectal adenoma were studied. 
These patients were classifi ed according to location, size of 
the longest axis, histological type, degree of cellular atypia 
and TCF4 protein expression of colorectal adenoma. Most of 
the cases studied were of adenomas with < 10 mm and with 
low-grade cellular atypia and tubular shape (Fig. 2).
Expression of TCF4 protein in 7 (13%) cases was observed. 
In adenoma subtypes larger than 30 mm, with severe atyp-
ia and villous histology, higher percentage of expression of 
TCF4 protein (42.9%, 25% and 33.3%, respectively) was noted, 
but the signifi cance of this difference could not be demon-
strated (Fig. 3).
Fig. 1 – Mean age of subjects, according to the group: 
carcinoma, adenoma and non-neoplastic colorectal tissue.
Fig. 2 – Distribution by gender of subjects according to the 
group: adenoma, carcinoma and non-neoplastic colorectal 
tissue.
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Of the 40 cases of patients with colorectal carcinoma, 
most were located in the rectum, classifi ed as II and III stag-
es, greater than 50 mm, moderately differentiated, without 
vascular compromise and without metastases. 
There was expression of TCF4 protein in 23 (57%) of sub-
jects with colorectal carcinoma. The expression of TCF4 
protein was compared, without significant difference with 
respect to gender (p = 0.52), age (p = 0.80), size (p = 0.20), 
grade of differentiation (p = 1.0), presence of metastasis 
(p = 1.0), vascular invasion (p = 1.0) and location (p = 0.80). 
The mean age of patients with carcinoma who expressed 
TCF4 protein was 65.5 ± 11.9 years; and of those who 
did not express the protein, the mean age was 66.4 ± 8.4 
years, without significant difference between these values 
(Fig. 4).
The analysis of non-neoplastic colorectal tissues showed 
expression of the protein in 6 (16%) cases (Fig. 5). 
We compared the expression of TCF4 protein between the 
group of patients with non-neoplastic colorectal tissue and 
the group of patients with colorectal adenoma. This compari-
son showed no signifi cant difference (p = 0.76) between the 
two groups. 
The comparison of the group with colorectal carcinoma 
versus colorectal adenoma and versus non-neoplastic colorec-
tal tissue showed signifi cant difference (p < 0.01) (Table 1).
Discussion
Genes stimulated by β-catenin/TCF4 complex act both in car-
cinogenesis as in the progression and formation of metasta-
sis of CRC.8 In this series, a signifi cant difference (p < 0.01) 
was observed between TCF4 protein immunoexpression in 
colorectal adenomas and carcinomas, suggesting a role of this 
protein in carcinogenesis. No signifi cant difference was found 
between non-neoplastic colorectal tissue and colorectal ad-
enoma. This fi nding indicates that the activity of this protein 
may occur in later stages of colorectal carcinogenesis.
To evaluate the role of TCF4 protein in the progression and 
formation of metastasis of CRC, we compared, in the cases of 
colorectal carcinoma studied, the expression of TCF4 protein 
in relation to the diameter, depth of invasion of the intestinal 
wall, vascular, lymph nodal and neural invasion, degree of dif-
Fig. 3 – Photomicrograph of colorectal adenoma with 
positive immunoexpression for the TCF4 antibody, 
represented by a brownish colour in the cell nucleus 
(immunohistochemistry ×200) (photo by the author).
Fig. 4 – Photomicrograph of colorectal adenoma with 
positive immunoexpression for the TCF4 antibody, 
represented by a brownish colour in the cell nucleus 
(immunohistochemistry ×200) (photo by the author).
Table 1 – Comparison of the expression of TCF4 protein 
in colorectal carcinoma, colorectal adenoma and non-
neoplastic colorectal tissue.
TCF-4 
protein 
expression
Colorectal 
carcinoma
Colorectal 
adenoma
Non-neoplastic 
colorectal 
tissue
Negative 17 (42,5%) 45 (86,5%) 31 (83,8%)
Positive 23 (57,5%) 7 (13,5%) 6 (16,2%)
Fig. 5 – Photomicrograph of colorectal adenoma 
with positive immunoexpression for TCF4 antibody, 
represented by a brownish colour in cell nucleus 
(immunohistochemistry × 200) (photo by the author).
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ferentiation, lymph node metastasis, and distant metastasis; 
in none of them a significant difference was found.
Despite evidence of the participation of TCF4 protein in 
the homeostasis of normal colorectal tissue and in colorec-
tal carcinogenesis, we found only one trial in literature that 
compared the expression of TCF4 protein in adenomas and 
colorectal carcinomas by immunohistochemistry studies.14 
The authors of this trial studied 68 cases of colorectal tu-
mours (19 adenomas, 14 adenomas with intraepithelial neo-
plasia and 35 carcinomas), and compared these tumours with 
the mucosa adjacent to the lesion. These authors found a dif-
ference between expression of TCF4 protein in the adenoma 
and in the adjacent normal mucosa, but no difference be-
tween the expression in the adenocarcinoma and in the ad-
jacent mucosa. This result may have been obtained by these 
authors thanks to the comparison made with the mucosa 
from the same individual and not from individuals with non-
neoplastic colon epithelium. Other reasons that may explain 
this difference may be linked to the smaller number of cases 
analyzed, as well as the different types of antibodies used, 
including with different dilutions (1:200).
In the present study, we observed that the non-neoplastic 
colorectal tissue and the colorectal adenoma expressed TCF4 
protein in less than 20% of cases. Although without signifi-
cant difference, the adenomas with higher probability of ma-
lignant transformation (larger ones, with a higher degree of 
atypia, and of histologic villous type) tended to express more 
frequently the protein. Possibly due to the high percentage of 
cases that did not express TCF4 protein among adenomas (> 
80%), we were unable to establish this difference. These data 
suggest that a future study with a larger sample may establish 
significant differences with respect to the expression of TCF4 
protein among tumours with low probability of neoplastic 
transformation and with high probability of transformation.
Kriegl et al.15 correlated the survival of patients operated 
on for colorectal carcinoma with expression of TCF4 protein. 
They identified the expression of TCF4 protein in 46% of cases, 
whose survival was worse. In the current series, although the 
prognosis has not been studied, there was expression of the 
protein in 57% of cases of carcinoma, a result similar to that 
obtained by Kriegl et al.15 Comparing the positivity of immu-
noexpression of TCF4 protein in relation to depth of invasion 
of the intestinal wall, lymph node invasion and presence of 
metastasis – data that may indicate a worse prognosis –, there 
was no significant difference. Such data can corroborate the 
fact that this protein is linked more to colorectal carcinogene-
sis, not participating in the processes considered as occurring 
in a later period in the progression of neoplasia, for instance, 
the invasion of adjacent tissue and occurrence of metastasis.
The difference in the expression of TCF4 protein between 
colorectal adenomas and carcinomas suggests that this pro-
tein participates in colorectal carcinogenesis, which is in 
agreement with the findings of van de Wetering et al.16 These 
authors stated that the β-catenin/TCF4 complex is the main 
regulator of proliferation and differentiation of the non-neo-
plastic colorectal tissue and in colorectal carcinomas; these 
authors also showed that the activation of TCF4 target genes, 
induced by mutations in the Wnt signalling pathway, consti-
tute the transforming event of the normal colorectal mucosa 
in neoplastic mucosa.
Kendiziorra et al.33 studied colorectal carcinoma cell lines 
and found that tumour cells that showed overexpression of 
TCF4 protein did not respond satisfactorily to radiotherapy. 
Moreover, the authors reported that the silencing of this 
overexpression renders these tumour cell lines more radio-
sensitive. The confirmation of these data by other studies 
can confirm the clinical importance of evaluating the ex-
pression of this protein for planning the treatment of CRC.
Chen et al.17 published studies on resveratrol, a substance 
found in plants, which could suppress the Wnt signalling 
pathway. In vitro analysis showed that this action occurs 
due to rupture of the β-catenin-TCF4 complex, suggesting 
that this mechanism of action may be a potential target for 
therapy of CRC. The reported studies show promise for the 
use of TCF4 protein as a therapeutic target in CRC. Consid-
ering that immunohistochemistry is a cheap and affordable 
method, it is important to determine patterns of TCF4 pro-
tein immunoexpression in non-neoplastic colorectal tissue 
and in colorectal adenomas and carcinomas.
The results reported in this study may help in the under-
standing of TCF4 protein activity and Wnt signalling path-
way in colorectal carcinogenesis, and thereby increase the 
prospect to finding new therapeutic targets for drug devel-
opment for the treatment of colorectal carcinoma.
Conclusions
Under the conditions of this study, the results showed that: 
1) The immunoexpression of TCF4 protein in colorectal car-
cinoma was superior versus in adenoma and non-neo-
plastic colorectal tissue. 
2) There was no difference of immunoexpression of TCF4 
protein in adenoma and in non-neoplastic colorectal epi-
thelium.
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